Optical coherence tomography findings in bioresorbable vascular scaffolds thrombosis by Cuculi, Florim et al.
Stent thrombosis (ST) is an uncommon but devastating adverse event after percutaneous coronary intervention 
(PCI).1 Various factors inﬂuence the likelihood of ST, such as 
patient-related characteristics, procedural and lesion charac-
teristics, the presence of acute coronary syndrome, or the pre-
mature discontinuation of antiplatelet therapy.2–6 Experiences 
with early generation drug-eluting stents (DES) demonstrated 
the crucial impact of pathological vessel healing and hyper-
sensitivity reactions to one of the components of the stent in 
the genesis of late ST.4,6,7 To decrease the incidence of these 
phenomena, the technology evolved from more biocompatible 
DES to fully bioresorbable vascular scaffolds (BVS).
Among BVS, the everolimus-eluting Absorb BVS (Abbott 
Vascular, Santa Clara, CA) are the most commonly implanted. 
Based on the evidence of safety demonstrated in early trials,8–10 
Absorb BVS have been subsequently launched to unrestricted 
clinical use in August 2012 in Europe. To date, >60 000 patients 
have been treated. Although the recently presented randomized 
Absorb II11 and EverBio-212 trials suggest similar efﬁcacy com-
pared with DES, some concerns about an increased rate of scaf-
fold thrombosis (ScT) arose. Indeed, the Gauging Coronary 
Healing With Bioresorbable Scaffolding Plaforms in Europe 
(GHOST-EU) registry reported a 2.1% incidence of deﬁnite 
ScT at 6 months.13 Along with this evidence, isolated small case 
series were reported, describing possible pathophysiological 
mechanisms of ScT and its putative therapeutic options.14–16
Optical coherence tomography (OCT) imaging has proved 
instrumental in identifying the mechanisms of scaffold fail-
ure and vessel healing after BVS implantation. Therefore, the 
aim of this study was to investigate the structural ﬁndings in 
patients presenting with ScT at our institutions.
Methods
Patient Population
Between December 2012 and October 2014, 26 patients had deﬁnite ScT 
after BVS implantation at our institutions. Since January 2014, a protocol 
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was implemented to perform OCT before emergency PCI in patients 
presenting with ScT. During this time period, 14 consecutive patients in 
whom deﬁnite ScT occurred were investigated by OCT and constitute 
the study population for this report. Clinical data were collected in an 
anonymized way with the approval of the local Ethics Committees.
Bioresorbable Vascular Scaffold
All included patients were treated with the ABSORB (Abbott 
Vascular, Abbott Park, IL) BVS version 1.1. BVS became available 
for all-comer use in June 2012 in Fribourg, in May 2012 in Mainz, 
and in July 2013 in Luzern.
Deﬁnition of Scaffold Thrombosis
ScT was deﬁned in analogy to the deﬁnitions for ST proposed by 
the Academic Research Consortium in 2007.1 Thus, the presence of 
a thrombus that originated in the scaffold or its 5 mm proximal or 
distal margins on angiographic or intravascular examination and the 
presence of either (1) acute onset of ischemic symptoms, (2) new 
ECG changes that suggest ischemia, (3) typical rise and fall in cardiac 
biomarkers, or a combination of the latter deﬁned ScT. Nonocclusive 
thrombi on angiographic examination were deﬁned as noncalci-
ﬁed ﬁlling defect or lucency surrounded by contrast material seen 
in multiple projections, or persistence of contrast material within 
the lumen, or a visible embolization of intraluminal material down-
stream. Occlusive thrombi were considered with a Thrombolysis in 
Myocardial Infarction ﬂow of 0 or 1 either intrascaffold or proximal 
to a scaffold up to the most adjacent proximal side branch or main 
branch (if originates from the side branch). On OCT, ScT was identi-
ﬁed as mass attached to the luminal surface or ﬂoating within the lu-
men of the scaffold or its 5 mm proximal and distal margins.17 Timing 
of ScT was deﬁned according to the Academic Research Consortium 
criteria for ST as early (<30 days after implantation), late (>30 days to 
1 year after implantation), and very late (>1 year after implantation).
Quantitative Coronary Angiography
Coronary angiograms were recorded digitally at baseline after index 
procedure and at the time of ScT. All analyses were performed at 
the angiographic core laboratory of the University and Hospital of 
Fribourg. QCA were computed with dedicated software (CAAS II; 
Pie Medical Imaging, Maastricht, The Netherlands) that uses auto-
mated edge detection. Quantitative measurements included reference 
vessel diameter, minimal luminal diameter, percent diameter stenosis 
(calculated as 100×[reference vessel diameter−minimal luminal di-
ameter]/reference vessel diameter), and lesion length.
OCT Acquisition and Analysis
OCT images were acquired before emergency PCI. After the diag-
nostic angiography, 200 μg of intracoronary nitroglycerin was ad-
ministered. OCT was performed with the Optis Ilumien system (St 
Jude Medical, MN) according to manufacturer guidelines using the 
Dragonﬂy Duo OCT Imaging Catheter with motorized pullback (25 
mm/s) and the nonocclusive ﬂushing technique. Images of the scaf-
fold and of the reference segments 10 mm proximal and distal of 
the scaffold were acquired. OCT pullbacks were registered on CD-
ROM and assessed ofﬂine by 2 assessors using dedicated software 
(Lightlab Imaging, St. Jude Medical, MN).
Quantitative measurements were performed at intervals of 0.6 
mm whenever quality image allowed for it and comprised the cross-
sectional area (CSA) of the external elastic membrane (mm2) and the 
lumen (mm2) of reference and treated segments. In addition, the mean 
and minimal scaffolds CSA (mm2) were recorded. Neointimal hyper-
plasia was calculated as scaffold CSA minus in-scaffold lumen CSA. 
Incomplete scaffold apposition (ISA) was deﬁned as a lack of contact 
of at least 1 strut at a distance of ≥163 μm to the underlying vessel 
wall in the absence of a side branch with evidence of blood ﬂow be-
hind the strut. ISA CSA was deﬁned as in-scaffold lumen CSA minus 
scaffold CSA. Scaffold expansion index was calculated in dividing 
the minimal scaffold CSA by the mean proximal and distal lumen 
CSA. Scaffold underexpansion was deﬁned as a stent expansion in-
dex 0.8. Undersizing was deﬁned as the employment of a scaffold 
whose deployment at implantation pressure resulted in an incomplete 
stent apposition with a distance of >100 μm of the abluminal stent 
edge from the adjacent vessel wall.
Neoatherosclerosis was deﬁned as the presence of either (1) ﬁbro-
calciﬁc plaques (signal-poor regions with sharply delineated upper and 
lower borders) or (2) lipid-rich plaques (diffusely bordered, signal-poor 
regions) on the luminal side of scaffold struts.18 Because they share 
the same OCT appearance (homogenous, highly backscattering lesions 
devoid of OCT signal-poor regions) and histology, no discrimination 
was made between ﬁbrotic plaques and neointima. Neovessels were 
deﬁned as sharply delimitated signal-poor lacunae that extended over 
multiple contiguous frames. Peristrut low-intensity areas (PSLIA) 
were deﬁned according to Otake et al as homogenously appearing, 
nonsignal-attenuating zones around struts of lower intensity than the 
surrounding tissue.19 Peristrut intensity was measured at the midstrut 
at 150 μm depth from the lumen and at equal distance between 2 con-
tiguous struts based on intensity of the key component of the cyan, 
magenta, yellow, key/black (CYMK) color model based on raw cross-
sectional images. PSLIA in each patient was judged as either present 
or absent by 3 independent observers. Two observers performed ratings 
on 2 different occasions to allow the assessment of intraobserver reli-
ability. Scaffold fracture was suspected in case of altered scaffold ge-
ometry appearing as 2 overlapping rows of at least 2 contiguous struts 
on a portion of the circumference in the absence of scaffold overlap or 
lack of circumferential struts.
Thrombus Harvesting, Histopathologic Sampling, 
and Analysis
Before emergency PCI, patients underwent thrombus aspiration fol-
lowed immediately by OCT acquisition of the affected scaffold segment 
as already published.6 In brief, if the hemodynamic status allowed, sub-
lingual or intracoronary nitroglycerin was administered (0.2–0.3 mg), 
and an angiogram with the use of a 6F guiding catheter was performed 
to identify the site of thrombotic scaffold occlusion. Then, a 0.014-inch 
coronary guidewire was passed through the affected scaffold, followed 
by aspiration of thrombus with the use of speciﬁcally designed manual 
aspiration catheters. Harvested thrombus was passed through a 40-μm 
Becton Dickinson Cell Strainer ﬁlter and ﬁxed in 4% neutral buffer 
formalin. Parafﬁn blocks of the thrombotic material were sectioned 
on a rotary microtome and stained with hematoxylin–eosin, Movat 
WHAT IS KNOWN
s Thrombosis of bioresorbable vascular scaffolds has 
been reported recently.
s  Intravascular imaging, such as optical coherence 
tomography and intravascular ultrasound, can pro-
vide information as to the mechanism(s) of stent 
thrombosis.
WHAT THE STUDY ADDS
s We identiﬁed a relationship between early scaffold 
thrombosis to mechanical factors, such as underex-
pansion, undersizing, and geographical miss, as well 
as to inadequate antiplatelet treatment.
s The predominant optical coherence tomography 
ﬁnding in late and very late scaffold thrombosis is 
peristrut low-intensity area, which may be the cor-
relate of vascular edema, thus enhancing vascular 
vulnerability.
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pentachrome, and Luna stains. All sections were examined by light mi-
croscopy for platelets, ﬁbrin, red blood cells, plaque constituents, and 
inﬂammation. In addition, 5 high-power ﬁelds (×40) demonstrating the 
greatest severity of inﬂammation were selected for quantitative analysis. 
Total white blood cell (WBC) and eosinophil counts were performed 
and summed for the selected 5 high-power ﬁelds. Data were recorded as 
total WBCs and total eosinophils. The severity of the inﬂammation was 
graded on the basis of a 3-tiered scale deﬁned as (1) mild (<100 WBCs 
per high-power ﬁeld), (2) moderate (101–300 WBCs per high-power 
ﬁeld), and (3) severe (>300 WBCs per high-power ﬁeld).
Statistical Analysis
Statistical analysis was primarily descriptive. Categorical variables 
are presented as absolute counts and percentages, and continuous 
variables are presented as means and standard deviations or medians 
with 25th to 75th percentiles. For illustrative purposes, comparisons 
between early ScT and late/very late ScT were performed using the 
Wilcoxon rank-sum test. Inter-rater reliability was assessed using 
Fleiss’s kappa and intraobserver reliability using Cohen’s kappa. All 
statistical analyses were performed using dedicated software (Stata 
version 13; StataCorp LP, College Station, TX) at a 2-tailed signiﬁ-
cance level of α=0.05.
Results
Baseline Patient Characteristics
A total of 14 patients who had 15 ScT underwent OCT before 
emergency PCI and were included in the present study. Mean age 
was 59±10 years, and 79% (n=11) of patients were men. Smok-
ing and hypertension were the most prevalent risk factors found 
in 71% (n=10) of patients. Five (36%) patients had undergone 
PCI before BVS implantation. ST-elevation myocardial infarc-
tion was the most frequently encountered indication for index 
procedure (50%; n=7). Mean left ventricular ejection fraction was 
48±10%. Further baseline characteristics are outlined in Table 1.
Angiographic and Procedural Characteristics at 
Index Procedure
Baseline angiographic and procedural characteristics are sum-
marized in Table 2. Four (27%) patients presented with total 
coronary occlusion. Mean minimal luminal diameter was 
0.82±0.77 mm and mean diameter stenosis was 79±20%. The 
median number of implanted BVS per lesion was 1 [25%–75% 
interquartile range: 1–1]. BVS overlap was present in 2 (13%) 
patients. Final in-scaffold minimal luminal diameter was 
2.59±0.42 mm. All patients showed a Thrombolysis in Myo-
cardial Infarction ﬂow of 3 after BVS implantation.
Scaffold Thrombosis
Timing
Fifteen ScT occurred at a median of 16 days [25%–75% inter-
quartile range: 1–263 days]. There were 8 (53%) early ScT 
(median: 3 days) of whom 3 (20%) were acute and 5 (33%) 
subacute. ScT occurred late (median: 243 days) in 5 (33%) 
cases and very late (573 days) in 2 (14%) cases.
Qualitative OCT Findings
Table 3 provides information on antiplatelet medication, 
implanted devices, target vessel, presentation at index proce-
dure, and the presumed underlying mechanism of ScT in the 
individual patients as assessed by qualitative OCT interpretation.
Early ScT were presumably because of insufﬁcient plate-
let inhibition in 2 (13%) cases and procedural factors (scaf-
fold underexpansion, undersizing, or geographical miss) in 4 
(27%) cases. No obvious cause was found in 2 (13%) early 
ScT. Exemplary images of undersizing and underexpansion 
are shown in Figure 1.
In late and very late ScT, 5 (33%) scaffolds showed 
intimal neovessels or marked PSLIA as demonstrated in 
Figure 2. Intraobserver reliability for PSLIA showed perfect Table 1. Baseline Patient Characteristics (n=14)
Male, n (%) 11 (79)
Age, years±SD 59±10
Hypertension, n (%) 10 (71)
Diabetes mellitus, n (%) 2 (14)
Smoking, n (%) 10 (71)
Dyslipidemia, n (%) 8 (57)
Family history, n (%) 4 (29)
Previous MI, n (%) 1 (7)
Previous PCI, n (%) 5 (36)
Previous CABG, n (%) 1 (7)
Indication at index procedure
  Stable angina, n (%) 2 (14)
  Silent ischemia, n (%) 0 (0)
  Acute coronary syndrome 12 (86)
  Unstable angina, n (%) 3 (21)
  NSTEMI, n (%) 2 (14)
  STEMI, n (%) 7 (50)
LVEF, % ±SD 48±10
Multivessel disease, n (%) 6 (43)
CABG indicates coronary artery bypass grafting; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NSTEMI, non–ST-elevation myocardial 
infarction; PCI, percutaneous coronary intervention; SD, standard deviation; and 
STEMI, ST-elevation myocardial infarction.
Table 2. Lesion Characteristics at Index Procedure (N=15)
Target coronary artery
  LAD, n (%) 6 (40)
  LCX, n (%) 2 (13)
  RCA, n (%) 7 (47)
  Lesion length, mm 17.2±7.5
  Reference vessel diameter, mm 2.76±0.44
  Minimal luminal diameter, mm 0.82±0.77
  Diameter stenosis, % 79±20
  Number of scaffolds per lesion 1 (1–1)
  Total scaffold length, mm 26±14
  Scaffold diameter, mm 3.1±0.3
  Scaffold overlap, n (%) 2 (13)
Post-procedural characteristics
  Final in-scaffold minimal luminal diameter, mm 2.59±0.42
  Final in-scaffold diameter stenosis, % 12±7
  TIMI ﬂow 3 (3–3)
Values are expressed in mean±SD (standard deviation) or median with 
interquartile range (in brackets). LAD indicates left anterior descending artery; 
LCX, left circumﬂex artery; RCA, right coronary artery; and TIMI, Thrombolysis 
in Myocardial Infarction.
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(kappa=1.0; P<0.001) agreement, and interobserver reliabil-
ity showed almost perfect (kappa=0.86; P<0.001) agreement. 
Scaffold fractures were additionally found in 2 (13%) and scaf-
fold collapse additionally in 1 (7%) of latter patients. Extensive 
strut malposition was the presumed cause for ScT in 1 (7%) 
case. One (7%) scaffold did not show any abnormalities at the 
time point of thrombosis. Postprocedural OCTs (after ﬁnal 
treatment) were analyzed in 6 (40%) cases, and the volume 
Table 3. Narratives of 15 ScT
ID No.
Time to  
ScT, days Presumed Cause for ScT
Indication  
for Index PCI
Treated 
Vessels
Target 
Vessel
No. of BVS in  
Target Lesion
BVS Diameter, 
mm
BVS Length, 
mm
P2Y12  
Inhibitor
1 0 Patient did not receive DAPT/Undersized 
scaffold with ISA
STEMI 1 RCA 1 3.5 18 Prasugrel
2 0 Calciﬁed lesion UA 1 LAD 1 3 12 Prasugrel
3 0 Regional miss—de novo stenosis 
proximal to scaffold left untreated
STEMI 1 RCA 1 3 18 Ticagrelor
4 1 Calciﬁed lesion, asymmetrical 
apposition, fracture
Stable Angina 1 LAD 1 3 28 Prasugrel
5 4 Insufﬁcient platelet inhibition,* scaffold 
underexpansion
STEMI 1 LAD 1 3 18 Ticagrelor/ 
Clopidogrel
6 6 Undersized scaffold with ISA STEMI 1 RCA 1 2.5 28 Ticagrelor
7 8 Underexpansion, calciﬁed lesion NSTEMI 1 LAD 1 2.5 18 Ticagrelor
8 16 Organized thrombus in distal scaffold UA 2 LCX 1 2.5 28 Clopidogrel
9 73 No mechanistic explanation UA 2 RCA 2 3 56 Prasugrel
10 104 Focal restenosis after bifurcation, 
neovessels, ruptured restenosis
STEMI 1 LAD 1 3.5 28 Prasugrel
11 243 PSLIA, long scaffold fracture; NSTEMI 1 RCA 2 3 56 Prasugrel
12 263 PSLIA, neovessels Stable Angina 2 LAD 1 3 28 Prasugrel
13 349 ISA, PSLIA, BVS recoil? STEMI 1 RCA 2 3 28 Prasugrel
14 562 PSLIA, ISA, asymmetrical scaffold and 
fracture
STEMI 1 RCA 1 3.5 12 Prasugrel
15 584 PSLIA, scaffold collapse NSTEMI 1 LAD 1 3.5 12 Ticagrelor
BVS indicates bioresorbable vascular scaffold; DAPT, dual antiplatelet therapy; ISA, incomplete scaffold apposition; LAD, left anterior descending artery; LCX, left 
circumﬂex artery; NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PSLIA, peristrut low intensity area; RCA, right coronary 
artery; ScT, scaffold thrombosis; STEMI, ST-elevation myocardial infarction; and UA, unstable angina.
*Insufﬁcient platelet inhibition: Ticagrelor was stopped on day 3 after scaffold implantation and Clopidogrel was started on day 4 (75 mg, no loading). In the evening 
of day 4, the patient sustained ScT.
Figure 1. Early scaffold thrombosis (ScT). A, ScT 6 days after scaffold implantation for inferior ST-elevation myocardial infarction. Optical 
coherence tomography revealed undersizing in the proximal part of the scaffold as the key mechanism for ScT. B, ScT 8 days after scaffold 
implantation for non–ST-elevation myocardial infarction. Optical coherence tomography revealed underexpansion as the key mechanism for 
ScT: 3D reconstruction demonstrates an underexpanded distal segment with good expansion in the proximal segment of the scaffold.
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of residual thrombus computed (Table 4). No new evidence 
regarding the underlying mechanism of ScT was gathered.
Quantitative OCT Findings
Quantitative OCT analysis was conducted in all affected seg-
ments and is outlined in Table 5. Mean scaffold CSA was 
6.5±1.9 mm.2 Two (13%) segments presented a minimal scaf-
fold CSA of <4 mm.2 Mean scaffold expansion index was 
0.95±0.36, with 9 (60%) of segments presenting an index 
<0.8. When comparing early ScT with late and very-late 
ScT, the mean scaffold expansion index was not signiﬁcantly 
smaller in early ScT (0.88±0.12) versus late and very late ST 
(1.04±0.15, P=0.56). Any ISA was found in 8 (53%) seg-
ments. Latter presented a mean maximal ISA CSA of 1.3±1.3 
mm2 and a mean maximal ISA length of 3.4±4.1 mm. Moder-
ate neointimal hyperplasia was present in 6 out of 7 patients 
presenting with late and very late ScT. One patient presented 
with focal restenosis that ruptured and lead to ScT. None of 
the remaining patients, in whom the neointima was homog-
enous (4 patients with bright tissue and 1 patient with signal-
poor tissue extending abluminally beyond the scaffold struts), 
presented OCT ﬁndings consistent with neoatherosclerosis. 
In these patients, the mean neointima hyperplasia–CSA per 
analyzed frame was 1.3±1.0 mm.2 Finally, a lower light inten-
sity (higher Key component) was found in segments from 
patients presenting with late and very late ScT (20±16%) in 
comparison with patients presenting with early ScT (13±9%, 
P<0.001). This phenomenon is demonstrated in Figure 3.
Histopathologic Findings
A total of 3 thrombectomy specimens were submitted for 
histopathologic analysis. Qualitative histopathologic analysis 
of the thrombi showed fragments of ﬁbrin and platelet-rich 
thrombus with variable numbers of trapped red blood cells 
(Figure 2). None of the 3 thrombi demonstrated any signiﬁ-
cant acute or chronic inﬂammatory reaction. Of note, the num-
ber of eosinophils were within the normal range.
Discussion
This study used OCT imaging to explore BVS failure in 15 
ScT. The main ﬁndings are that (1) OCT ﬁndings are distinc-
tive in early ScT versus late or very late ScT, (2) early ScT 
is mostly related to inadequate antithrombotic regimen and 
implantation technique; and (3) late ScT is associated with 
lower peristrut light intensity (a surrogate marker of edema), 
neovessel formation, and scaffold fracture.
Early ScT: Undersizing and Underexpansion
Several reports have identiﬁed undersizing as a key factor 
for ST in both bare-metal stents and DES.20–23 In 2 out of 8 
patients sustaining early ScT, we identiﬁed undersizing as the 
key mechanism. In the case shown in Figure 1, a 2.5 mm scaf-
fold was implanted in a vessel with a diameter >3.5 mm. Not 
surprisingly, both patients with undersizing were treated for 
ST-elevation myocardial infarction during the index proce-
dure. It is well known that blood levels of potent vasoconstric-
tors, such as endothelin-1 and neuropeptide Y, are markedly 
elevated in patients with ST-elevation myocardial infarction, 
and although this has been mainly linked to microcirculatory 
dysfunction in the literature,24,25 it is likely that profound vaso-
constriction also affects epicardial arteries. The use of intra-
coronary vasodilators, such as nitroglycerine and adenosine, 
can probably help alleviating the problem of undersizing BVS 
in ST-elevation myocardial infarction.
Figure 2. Very late scaffold thrombosis (ScT). A, Angiographic and optical coherence tomography (OCT) ﬁndings in a 55-year-old man 
who presented with ScT 562 days after scaffold implantation. The OCT demonstrates diffuse peristrut low-intensity area (PSLIA) and 
strut discontinuities (*) along the scaffold length. B and C, Histological sections of harvested thrombus showed fragments of platelet-rich 
thrombus with rare signs of acute and chronic inﬂammation, including scarce eosinophils (B) and regions of organized thrombus with high 
amount of trapped red cells but no excess amount of inﬂammatory cells (C). Histology: H&E staining ×200.
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Underexpansion is a well-known risk factor for ST. In the 
present series, underexpansion was encountered in 2 patients, 
1 of whom presented a calciﬁed lesion. This may highlight 
the importance of lesion selection and optimal lesion prepa-
ration before BVS implantation. It moreover raises the ques-
tion regarding the radial strength of the current version of 
the Absorb BVS. In a study from 2007, acute recoil was 
compared between the Absorb BVS (revision 1.0) and the 
everolimus-eluting cobalt chromium stent. There was a trend 
toward more acute stent recoil in the Absorb BVS but the 
difference was not statistically signiﬁcant.26 In a later study, 
acute recoil was similar between Absorb BVS revision 1.0 
Table 4. OCT Characteristics and Postprocedural Findings
ID No OCT Runs
Failed or Very Poor  
Quality OCT Runs  
(Reason)
Percentage of Good 
Quality on Analyzed 
OCT Run(s)
Reason for  
Poor Quality
OCT at End of 
Procedure
Percentage of  
Good Quality OCT 
After Treatment
Residual 
Thrombus  
Burden, mm3 Final Treatment
1 2 1 (poor ﬂushing) 73% Backscattering/ 
attenuation because of 
thrombus
No Thrombus aspiration, 
PTCA with NC 3.0
2 5 0 100% None No PTCA with NC 3.0, 
implantation of another 
BVS proximal to the 
ﬁrst one
3 2 0 61% Backscattering/ 
attenuation because of 
thrombus
Yes 100% 14.13 PTCA with NC 3.0, 
implantation of a Xience 
3.0
4 3 1 (poor ﬂushing and 
occlusive thrombus)
71% Backscattering/ 
attenuation because of 
thrombus
No PTCA with Maverick 1.5 
≤2.5, NC 3.0,
5 3 1 (occlusive thrombus) 60% Backscattering/ 
attenuation because of 
thrombus
Yes 100% 4.93 Thrombectomy, direct 
stenting with DES
6 2 0 75% Poor ﬂushing in 
proximal part of BVS
Yes 100% 2.24 PTCA, DES
7 2 1 (poor ﬂushing) 83% Backscattering/ 
attenuation because of 
thrombus
No PTCA with 2.75 SC, OCT, 
2× implantation Xience 
2.75
8 1 0 75% Backscattering/ 
attenuation because 
of thrombus in distal 
scaffold
No PTCA, DES
9 4 1 (poor ﬂushing) 100% None Yes 90% (poor 
ﬂushing)
3.51 PTCA, DES
10 2 0 50% Backscattering/ 
attenuation because of 
thrombus
No PTCA without stent
11 4 0 73% Backscattering/ 
attenuation because of 
thrombus
Yes 95% (poor 
ﬂushing)
15.53 PTCA, DES
12 3 0 82% Backscattering/ 
attenuation because of 
thrombus
No Thrombectomy, DES 
(XIENCE) implantation 
with pre- and 
postdialation
13 1 0 50% Poor ﬂushing and 
catheter partly in false 
lumen
No Thrombus aspiration, 
PTCA with NC 3.5 and 
implantation of a BVS 3.5 
mm directly proximal to 
the BVS
14 3 1 (occlusive thrombus) 83% Backscattering/ 
attenuation because of 
thrombus
Yes 90% (poor 
ﬂushing)
2.57 Thrombus aspiration, 
PTCA with NC 3.5, Xience 
3.5
15 1 0 92% Backscattering/ 
attenuation because of 
thrombus
No No intervention
BVS indicates bioresorbable vascular scaffold; DES, drug-eluting stent; NC, noncompliant; OCT, optical coherence tomography; and PTCA, percutaneous transluminal 
coronary angioplasty.
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and 1.1 and slightly but not signiﬁcantly lower than metallic 
everolimus-eluting cobalt chromium stent.27 Of course, this 
difference might be even intensiﬁed in all-comer series of 
patients presenting with more complex lesions. Consistently, 
the acute recoil in the EverBio-2 trial was greater in BVS 
(9.5±6.5%) than in metallic comparators (6.6±4.7%, 
P<0.01).12
Late ScT: BVS Resorption, Peristrut Light 
Intensity, Neovessels, and Scaffold Rupture
Delayed healing has been identiﬁed as a possible mechanism 
of late/very late ST after implantation of early generation 
DES. The pathological correlate of this process was thought 
to be a lack of strut coverage,28,29 late acquired stent malap-
position,4 and late drug or polymer-related hypersensitiv-
ity reactions characterized by neutrophilic or eosinophilic 
inﬁltrates.6,30 A recently published study reported a com-
parison of vascular responses to the implantation of Absorb 
BVS versus a metallic everolimus-eluting cobalt chromium 
stent in nonatherosclerotic swines. Although there was no 
inﬂammation at 1 month for both devices, the inﬂammation 
scores were greater for the Absorb BVS at 6 to 36 months.31 
Interestingly, the authors described segments with late-
occurring strut discontinuities where the scaffold geometry 
was modiﬁed because of a low-grade inﬂammatory reaction 
with increasing eosinophils count and secondary integration 
of arterial tissue. The results of the present OCT study in ScT 
demonstrate a time-dependent increase in PSLIA together 
with neovessel formation and in vivo scaffold discontinui-
ties. This phenomenon is illustrated in Figure 2. Although 
the causes and consequences of PSLIA remain uncertain in 
BVS, a recently published trial in 26 coronary swine seg-
ments treated with everolimus-eluting DES demonstrates a 
direct correlation between the degree of PSLIA and peristrut 
inﬂammation at histology.32 PSLIA has been associated with 
malapposition, evaginations, strut fracture, and uncovered 
struts as possible mechanisms of a late in-stent/ScT.33,34 An 
association between PSLIA and the risk of thrombosis has 
been provided by a study on delayed healing and late throm-
botic risk after DES implantation in humans by Joner et al.30 
Alternatively—and as PSLIA is more frequently encoun-
tered with bioresorbable polymers—it could be a marker of 
vascular edema because of the hydrolysis of polylactide. Yet 
and as edema increases the vascular vulnerability, the asso-
ciation of this PSLIA pattern with the occurrence of late ScT 
is concerning.
Limitations
Some limitations that are inherent to the analysis of device 
thrombosis are true for the present study: Even though great 
care was taken to repeat OCT after sufﬁcient thrombec-
tomy, interpretation of pullbacks may be affected by poor 
image quality because of backscattering or light attenuation 
by thrombi. Furthermore, quantiﬁcation of residual throm-
bus may be adversely affected (inaccurate measurements) in 
regions where light attenuation or backscattering because of a 
thrombus did not allow for delineation of the underlying neo-
intima from the latter. Another limitation of the present study 
is the lack of a control group without ScT.
Conclusions
Although early BVS thrombosis seems similar to bare-metal 
stent or DES thrombosis, late and very late BVS thrombosis 
are associated with a different morphological OCT pattern. 
This suggests that vascular edema (with or without low-grade 
Table 5. Optical Coherence Tomography Measurements at the 
Time Point of Scaffold Thrombosis (n=15)
Reference segment
  EEM CSA, mm2 13.5±4.4
  Lumen CSA, mm2 7.9±4.2
Scaffold segment
  Maximal EEM CSA, mm2 14.8±4.0
  Remodeling index 1.1±0.2
  Scaffold CSA, mm2 6.5±1.9
  Minimal scaffold CSA, mm2 5.2±1.9
  Minimal scaffold CSA < 4 mm2, n (%) 2 (13)
  Scaffold expansion index 0.95±0.36
  Underexpanded scaffolds, n (%) 9 (60)
  In-scaffold lumen CSA, mm2 5.8±2.3
  Neo-intimal hyperplasia, mm2 1.3±1.0
  ISA, n (%) 8 (53)
   Maximal ISA CSA, mm2 1.3±1.3
   Maximal ISA depth, mm 0.5±0.4
   Maximal ISA length, mm 3.4±4.1
CSA indicates cross-sectional area; EEM, external elastic membrane; and 
ISA, incomplete scaffold apposition.
Figure 3. Occurrence of peristrut low-intensity areas increases over time. As illustration, the measurements of the intensity of the key 
component of the cyan, magenta, yellow, key/black (CYMK) color model are given for each cross-sectional image on bottom. The occur-
rence of ScT are marked as vertical lines on the time scale.
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inﬂammation) might be the prevailing pathophysiological 
mechanism of late ScT.
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